Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlook

Twenty years on from its initial approval as the first monoclonal antibody for the treatment of multiple sclerosis (MS), natalizumab remains a valuable high-efficacy treatment option for people with relapsing-remitting MS, with robust real-world evidence supporting its long-term efficacy and well-ch...

Celý popis

Podrobná bibliografie

Vydáno v:	Therapeutic advances in neurological disorders Ročník 18; s. 17562864251372752
Hlavní autoři:	Klotz, Luisa, Berger, Thomas, Brownlee, Wallace J., Chan, Andrew, Lycke, Jan, Oreja-Guevara, Celia, Palavra, Filipe, Sacca, Francesco, Sejbaek, Tobias, Weber, Martin S., Giovannoni, Gavin
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England SAGE Publishing 01.01.2025
Témata:	multiple sclerosis natalizumab Neurosciences Neurovetenskaper treatment strategies treatment strategies multiple sclerosis natalizumab
ISSN:	1756-2864, 1756-2856, 1756-2864
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!